Joshua Trujillo, PA
Medical · El Paso, TXNPI 1497260160
Payments from drug & device makers
Across 465 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$788
- Lundbeck LLC$774
- AbbVie$713
- Neurocrine Biosciences, Inc.$573
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$541
- plus $3K from 24 others
What the payments were for
- Food & beverage$7,713100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 68 | $1,200 |
| Otsuka America Pharmaceutical, Inc. | 51 | $788 |
| Lundbeck LLC | 51 | $774 |
| AbbVie | 53 | $713 |
| Neurocrine Biosciences, Inc. | 35 | $573 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 30 | $541 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $417 |
| Galderma Laboratories, L.p. | 5 | $378 |
| Sunovion Pharmaceuticals Inc. | 23 | $318 |
| Teva Pharmaceuticals USA, Inc. | 12 | $272 |
| E.r. Squibb & Sons, L.L.C. | 16 | $207 |
| Corium, LLC | 16 | $204 |
| Vanda Pharmaceuticals Inc. | 11 | $195 |
| Johnson & Johnson | 10 | $179 |
| Bausch Health US, LLC | 8 | $160 |
| Tris Pharma Inc | 8 | $144 |
| Axsome Therapeutics, Inc. | 8 | $137 |
| Ironshore Pharmaceuticals Inc. | 6 | $113 |
| Idorsia Pharmaceuticals US Inc | 5 | $83 |
| Eisai Inc. | 4 | $64 |
| Supernus Pharmaceuticals, Inc. | 3 | $62 |
| Merck | 3 | $38 |
| Avanir Pharmaceuticals, Inc. | 2 | $28 |
| Noven Therapeutics, LLC | 1 | $24 |
| Lilly USA, LLC | 1 | $22 |
| Vertical Pharmaceuticals, LLC | 1 | $20 |
| Validus Pharmaceuticals LLC | 1 | $17 |
| Neos Therapeutics, LP | 1 | $16 |
| Almatica Pharma LLC | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,713 in reported general payments places this provider in the 90th percentile of 1,490 medical providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 14 | $120,699 |
| Austedo XrDeutetrabenazine | 19 | $85,625 |
| LybalviOlanzapine/Samidorphan Malate | 16 | $35,236 |
| TrintellixVortioxetine Hydrobromide | 42 | $33,242 |
| Invega SustennaPaliperidone Palmitate | 12 | $25,701 |
| VraylarCariprazine Hcl | 15 | $21,294 |
| Lurasidone Hcl | 63 | $19,680 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 30 | $4,093 |
| Aripiprazole | 73 | $2,468 |
| Divalproex Sodium ErDivalproex Sodium | 27 | $2,379 |
| Quetiapine Fumarate | 138 | $2,082 |
| Bupropion XlBupropion Hcl | 95 | $1,381 |
| Olanzapine | 49 | $1,217 |
| Clonazepam | 147 | $1,046 |
| Duloxetine Hcl | 38 | $1,021 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $573 | $120,69914 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $272 | $85,62519 claims |
| Alkermes, Inc.Lybalvi | $1,200 | $35,23616 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $417 | $33,24242 claims |
| Johnson & JohnsonInvega Sustenna | $179 | $25,70112 claims |
| AbbVieVraylar | $713 | $21,29415 claims |
| Lilly USA, LLCOlanzapine | $22 | $1,21749 claims |
| Almatica Pharma LLCSertraline Hcl | $15 | $43667 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,490 medical providers in Texas.
Other medical in El Paso
- Jose de la CerdaSan Antonio$1.1M
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Courtney AldridgeSan Antonio$129K
- Shakira CabreraSan Antonio$116K
- Danny DeckardDallas$101K
- Janine ShinnDallas$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.